Parameters | n | Hazard ratio (95% CI) | p value |
---|---|---|---|
Age | 1.05 (0.98–1.12) | 0.19* | |
Gender | |||
Female | 17 | 1 | 0.72 |
Male | 64 | 1.21 (0.52–3.65) | |
PS (ECOG) | |||
0 | 55 | 1 | 0.61 |
1–2 | 26 | 1.23 (0.42–3.65) | |
T stage | |||
T1a | 42 | 1 | |
T1b, T2a | 39 | 2.38 (1.05–5.39) | 0.04* |
CTV | 1.01 (1.00–1.03) | 0.05* | |
PTV | 1.00 (0.99–1.01) | 0.29 | |
Histology | 0.78 | ||
Adenocarcinoma | 35 | 1 | |
Squamous cell carcinoma | 27 | 1.46 (0.47–4.57) | 0.51 |
Unproven | 17 | 1.18 (0.35–3.92) | 0.79 |
Tumor location | |||
Peripheral | 6 | 1 | |
Central | 75 | 1.29 (0.30–5.51) | 0.73 |
Operability | |||
Yes | 21 | 1 | |
No | 60 | 1.03 (0.43–2.43) | 0.94 |
Total dose | |||
48 Gy | 60 | 1 | |
60 Gy | 21 | 0.99 (0.93–1.07) | 0.87 |